CareDx (NASDAQ: CDNA) saw its shares plummet 5.15% in pre-market trading on Thursday, following the release of its Q1 2025 earnings report. Despite reporting strong revenue growth, investors appear concerned about increased expenses and potential challenges ahead for the transplant diagnostics company.

The company reported an 18% year-over-year increase in revenue, reaching $84.7 million for the first quarter. CareDx also achieved its seventh consecutive quarter of sequential testing volume growth, with testing services revenue up 15% compared to the previous year. However, these positive results were overshadowed by several factors that may have contributed to the stock's decline.

One key concern for investors appears to be the increase in operating expenses, primarily driven by investments in sales and marketing. While these investments are aimed at future growth, they could potentially impact profitability in the short term. Additionally, the company faced a $1.1 million write-off for aged receivables, indicating potential challenges in collections. CareDx is also involved in a securities class action litigation, with an anticipated out-of-pocket expense of approximately $5.4 million, which may have further dampened investor sentiment.

Looking ahead, CareDx noted a muted start to the year in transplant procedures, which could impact future revenue growth if not addressed. The company also announced plans for a $5 million annual investment for Epic integration, which, while potentially beneficial in the long run, could strain resources in the near term. These factors, combined with the overall market's cautious approach to healthcare stocks, likely contributed to the significant drop in CareDx's share price, despite its strong revenue performance.